Gastropanel for Gastric Atrophy and Cancer Risk Assessment

UnknownOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

October 31, 2018

Study Completion Date

January 31, 2019

Conditions
Gastritis, AtrophicStomach Neoplasms
Interventions
PROCEDURE

GastroPanel test

Dyspeptic patients will be referred for the GastroPanel test, containing four biomarkers specific for the gastric mucosa: 1) Pepsinogen I (P-PGI), 2) Pepsinogen II (P-PGII), 3) Gastrin-17 (P-G-17) and 4) H. pylori antibody (P-HpAb).

PROCEDURE

Gastroscopy

Dyspeptic patients will undergo gastroscopy examination, with targeted biopsies from the antrum and corpus, following the protocol of the OLGA classification for chronic gastritis and Sydney Classification.

Trial Locations (1)

E9 6SR

RECRUITING

Homerton University Hospital, London

Sponsors
All Listed Sponsors
lead

Biohit Healthcare Ltd

INDUSTRY

NCT02114411 - Gastropanel for Gastric Atrophy and Cancer Risk Assessment | Biotech Hunter | Biotech Hunter